A detailed history of Alliancebernstein L.P. transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 150,821 shares of SWTX stock, worth $5.47 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
150,821
Previous 140,242 7.54%
Holding current value
$5.47 Million
Previous $5.28 Million 8.52%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$32.04 - $42.76 $338,951 - $452,358
10,579 Added 7.54%
150,821 $4.83 Million
Q2 2024

Aug 14, 2024

BUY
$36.06 - $47.62 $2.55 Million - $3.37 Million
70,712 Added 101.7%
140,242 $5.28 Million
Q1 2024

May 14, 2024

BUY
$36.5 - $52.5 $114,610 - $164,850
3,140 Added 4.73%
69,530 $3.42 Million
Q2 2023

Aug 15, 2023

BUY
$23.15 - $32.71 $710,473 - $1 Million
30,690 Added 85.97%
66,390 $1.74 Million
Q2 2022

Aug 15, 2022

BUY
$18.36 - $60.07 $18,360 - $60,070
1,000 Added 2.88%
35,700 $879,000
Q1 2022

May 13, 2022

BUY
$48.97 - $65.46 $4,897 - $6,545
100 Added 0.29%
34,700 $1.96 Million
Q4 2021

Feb 14, 2022

BUY
$53.3 - $75.84 $21,320 - $30,336
400 Added 1.17%
34,600 $2.15 Million
Q3 2021

Nov 10, 2021

SELL
$62.66 - $88.26 $125,320 - $176,520
-2,000 Reduced 5.52%
34,200 $2.17 Million
Q2 2021

Jul 30, 2021

BUY
$67.45 - $85.63 $134,900 - $171,260
2,000 Added 5.85%
36,200 $2.98 Million
Q1 2021

May 06, 2021

BUY
$65.1 - $93.59 $39,060 - $56,154
600 Added 1.79%
34,200 $2.52 Million
Q4 2020

Feb 08, 2021

BUY
$48.36 - $77.92 $193,440 - $311,680
4,000 Added 13.51%
33,600 $2.44 Million
Q3 2020

Nov 12, 2020

BUY
$36.14 - $51.99 $57,824 - $83,184
1,600 Added 5.71%
29,600 $1.41 Million
Q2 2020

Aug 13, 2020

BUY
$22.98 - $48.57 $388,362 - $820,833
16,900 Added 152.25%
28,000 $1.18 Million
Q1 2020

May 14, 2020

BUY
$20.44 - $41.21 $226,884 - $457,431
11,100 New
11,100 $300,000

Others Institutions Holding SWTX

About SpringWorks Therapeutics, Inc.


  • Ticker SWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,401,100
  • Market Cap $2.27B
  • Description
  • SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...
More about SWTX
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.